Literature DB >> 23388

Determination of water soluble imidazo-1,4-benzodiazepines in blood by electron- capture gas--liquid chromatography and in urine by differential pulse polaragraphy.

C V Puglisi, J C Meyer, L D'Arconte, A Brooks, J A de Silva.   

Abstract

A sensitive and specific electron-capture gas--liquid chromatographic (GLC--ECD) assay was developed for the determination of 8-chloro-6-(2'-fluorophenyl)-1-methyl-4H-imidazo(1,5a)(1,4)benzodiazepine (I) or 8-chloro-1,4-dimethyl-6-(2'-fluorophenyl)-4H-imidazo (1,5a)(1,4)benzodiazepine (II) in blood. The assay for both compounds involves extraction into benzene--methylene chloride (9:1) from blood buffered to pH 12.6 The overall recovery of I and II from blood is 86% +- 5.0 (S.D.) and the sensitivity limit of detection is of the order of 2 to 3 ng of I or II per milliltre of blood. The major urinary metabolite of I is 8-chloro-6-(2'-fluorophenyl)-1-hydroxymethyl-4H-imidazo(1,5a)(1,4)benzodiazepine, (IA) present as a glucuronide conjugate while 8-chloro-6-(2'-fluorophenyl)-4-hydroxyl-1-methyl-4H-imidazo(1,5a)(1,4)benzodiazepine, (IB) and 8-chloro-6-(2'-fluorophenyl)-4-hydroxy-1-hydroxymethyl-4H-imidazo(1,5a)(1,4) benzodiazepine, (IC) are minor metabolites. The major metabolite IA is extracted into benzene--methylene chloride (9:1) from urine buffered to pH 11.0 (after incubation with glucuronidase--sulfatase as pH 5.0), and analyzed by differential pulse polarography (DPP) in 0.1 M phosphate buffer PH 3). The overall recovery of IA is 84 +- 3.0% (S.D.) with a sensitivity limit of 50 ng per millilitre of urine. The metabolites of compound II have not as yet been elucidated. The GLC--ECD and DPP assays were applied to the determination of blood levels and urinary excretion in dogs following single 10 mg/kg intravenous and oral doses of I and following single 6 mg/kg intravenous and 10 mg/kg oral doses of II. Blood levels of compound I were also evaluated in man following intravenous infusion of single 10 mg doses.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 23388     DOI: 10.1016/s0378-4347(00)81670-9

Source DB:  PubMed          Journal:  J Chromatogr


  14 in total

1.  Increased volume of distribution prolongs midazolam half-life.

Authors:  R J Wills; K C Khoo; P P Soni; I H Patel
Journal:  Br J Clin Pharmacol       Date:  1990-02       Impact factor: 4.335

2.  [Analytic data of the new benzodiazepine derivative midazolam (Dormicum) and its metabolites].

Authors:  H Schütz
Journal:  Z Rechtsmed       Date:  1985

3.  Chemical structure and properties of midazolam compared with other benzodiazepines.

Authors:  M Gerecke
Journal:  Br J Clin Pharmacol       Date:  1983       Impact factor: 4.335

4.  Pharmacokinetics and bioavailability of midazolam in man.

Authors:  P Heizmann; M Eckert; W H Ziegler
Journal:  Br J Clin Pharmacol       Date:  1983       Impact factor: 4.335

5.  Midazolam maleate induction in patients with ischaemic heart disease: haemodynamic observations.

Authors:  J G Reves; P N Samuelson; S Lewis
Journal:  Can Anaesth Soc J       Date:  1979-09

6.  Midazolam compared with thiopentone as a hypnotic component in balanced anaesthesia: a randomized, double-blind study.

Authors:  J G Reves; R Vinik; A M Hirschfield; C Holcomb; S Strong
Journal:  Can Anaesth Soc J       Date:  1979-01

7.  Sedative and respiratory effects of intramuscular midazolam as a premedicant: Influence of gender.

Authors:  Toshiyuki Yano; Yoshikazu Haratake; Kenji Urata; Tohru Morioka
Journal:  J Anesth       Date:  1994-12       Impact factor: 2.078

8.  The pharmacokinetics of midazolam in man.

Authors:  M T Smith; M J Eadie; T O Brophy
Journal:  Eur J Clin Pharmacol       Date:  1981-03       Impact factor: 2.953

9.  Assay of midazolam and brotizolam in plasma by a gas chromatographic and a radioreceptor technique.

Authors:  R Jochemsen; P A Van Rijn; T G Hazelzet; D D Breimer
Journal:  Pharm Weekbl Sci       Date:  1983-12-16

10.  Pharmacokinetics of midazolam in the aged.

Authors:  M T Smith; V Heazlewood; M J Eadie; T O Brophy; J H Tyrer
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.